| Element List | Explanation |
|---|---|
| Introduction | With reference to the announcement made by Dallah Healthcare Company (“Dallah” or the “Company”) on the Saudi Exchange website on 16/02/1446H (corresponding to 20/08/2024G) regarding the entry into a binding acquisition and subscription agreement (the “Agreement”) with Ayyan Investment Company (“Ayyan”) to acquire Ayyan’s shares in Al-Ahsa Medical Services Company, amounting to (97.41%) of the capital of Al-Ahsa, and to acquire Ayyan’s shares in Al-Salam Medical Services Company, amounting to (100%) of the capital of Al-Salam, in consideration for issuing new shares in Dallah to Ayyan (the “Transaction”), and whereas the Capital Market Authority issued its approval on Dallah’s capital increase for the purpose of the Transaction on 06/08/1446H (corresponding to 05/02/2025G), and in reference to the announcement made by the Company on the Saudi Exchange’s website on 20/08/1446H (corresponding to 19/02/2025G) whereby the Company’s board of directors invited the shareholders to attend the extraordinary general assembly meeting that includes the increase of the Company's capital (the first meeting), which is scheduled to be held at 9:00 PM on Wednesday 12/09/1446H (corresponding to 12/03/2025G) via means of modern technology to vote on the resolutions relating to the Transaction, Dallah is pleased to announce the publication of the shareholders circular issued by the Company to its shareholders in accordance with the requirements of Article (60) of the Rules on the Offer of Securities and Continuing Obligations in connection with the increase in the share capital of the Company for the purpose of the Transaction (the “Shareholders Circular”), which can be found on the Capital Market Authority's website and the following link: https://www.dallahhealth.com/Library/Assets/DallahHealth.pdf The board of directors of the Company emphasizes that each shareholder must carefully read and consider all information contained in the Shareholders Circular prior to making their decision on how to vote on the Transaction. If in doubt as to the vote that such shareholder should make at the Company’s extraordinary general assembly meeting, an independent financial advisor licensed by the CMA should be consulted, and the shareholder must rely on their own review of the Transaction to ensure the suitability of the Transaction and the information contained in the Shareholders Circular in light of their investment objectives and financial situation. The Company will announce any further material developments about the Transaction as it occurs. |
| Previous Announcement | Dallah Healthcare Company’s invite to its shareholders to attend the extraordinary general assembly meeting which includes the increase of the company’s capital (first meeting) |
| Date of Previous Announcement on Saudi Exchange’s Website | 2025-02-19 Corresponding to 1446-08-20 |
| Hyperlink to the Previous Announcement on the Saudi Exchange Website | Click Here |
| Latest Developments Of The Announced Event | The publication of the shareholder circular. |
| Reasons For The Delay on The Date of The Event Previously Announced | N/A |
| The costs associated with the event, and if they have changed or not with indication of the reasons. | N/A |
| Delay consequences on the Company’s financial results | N/A |
